Information Provided By: 
Fly News Breaks for December 21, 2017
PRTA
Dec 21, 2017 | 07:52 EDT
Cantor Fitzgerald analyst William Tanner lowered his price target for Prothena to $65 after the company guided to the last event in the VITAL Phase 3 study likely occurring in the second half of 2019 versus the latter part of 2018 as previously expected. The analyst, however, believes the delay does little to change the long-term investment thesis. He keeps an Overweight rating on Prothena.
News For PRTA From the Last 2 Days
There are no results for your query PRTA
